- Home
- KPTI vs SKYE Comparison
KPTI vs SKYE Comparison
Compare KPTI & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- SKYE
- Stock Information
- Founded
- KPTI 2008
- SKYE 2012
- Country
- KPTI United States
- SKYE United States
- Employees
- KPTI N/A
- SKYE N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- SKYE Health Care
- Exchange
- KPTI Nasdaq
- SKYE Nasdaq
- Market Cap
- KPTI 44.5M
- SKYE 73.4M
- IPO Year
- KPTI 2013
- SKYE N/A
- Fundamental
- Price
- KPTI $4.37
- SKYE $3.74
- Analyst Decision
- KPTI Buy
- SKYE Buy
- Analyst Count
- KPTI 6
- SKYE 6
- Target Price
- KPTI $48.50
- SKYE $16.60
- AVG Volume (30 Days)
- KPTI 55.7K
- SKYE 2.0M
- Earning Date
- KPTI 08-05-2025
- SKYE 08-08-2025
- Dividend Yield
- KPTI N/A
- SKYE N/A
- EPS Growth
- KPTI N/A
- SKYE N/A
- EPS
- KPTI N/A
- SKYE N/A
- Revenue
- KPTI $142,126,000.00
- SKYE N/A
- Revenue This Year
- KPTI $2.09
- SKYE N/A
- Revenue Next Year
- KPTI $12.90
- SKYE N/A
- P/E Ratio
- KPTI N/A
- SKYE N/A
- Revenue Growth
- KPTI 1.19
- SKYE N/A
- 52 Week Low
- KPTI $3.51
- SKYE $1.14
- 52 Week High
- KPTI $16.95
- SKYE $8.26
- Technical
- Relative Strength Index (RSI)
- KPTI 42.53
- SKYE 66.59
- Support Level
- KPTI $4.12
- SKYE $2.12
- Resistance Level
- KPTI $4.64
- SKYE $5.75
- Average True Range (ATR)
- KPTI 0.27
- SKYE 0.55
- MACD
- KPTI 0.03
- SKYE 0.17
- Stochastic Oscillator
- KPTI 32.97
- SKYE 45.82
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.